CSIMarket
 
Immunoprecise Antibodies Ltd   (NASDAQ: IPA)
Other Ticker:  
 
 
Price: $1.9300 $0.11 6.044%
Day's High: $1.99 Week Perf: 15.92 %
Day's Low: $ 1.81 30 Day Perf: 164.42 %
Volume (M): 1,441 52 Wk High: $ 2.32
Volume (M$): $ 2,780 52 Wk Avg: $0.60
Open: $1.82 52 Wk Low: $0.27



 Market Capitalization (Millions $) 49
 Shares Outstanding (Millions) 26
 Employees 142
 Revenues (TTM) (Millions $) 19
 Net Income (TTM) (Millions $) -21
 Cash Flow (TTM) (Millions $) 6
 Capital Exp. (TTM) (Millions $) 1

Immunoprecise Antibodies Ltd
Immunoprecise Antibodies Ltd is a biotechnology company that specializes in the discovery and development of novel therapeutic antibodies for the treatment of various diseases. The company utilizes advanced antibody discovery platforms and cutting-edge technologies to generate high-quality antibodies with desirable characteristics, including specificity, affinity, and stability.

Immunoprecise Antibodies offers a range of services, including antibody discovery, development, engineering, and production. They work with pharmaceutical and biotechnology companies, as well as academic institutions, to accelerate the development of innovative antibody-based therapeutics.

The company's state-of-the-art facilities and experienced team of scientists enable them to provide comprehensive solutions for antibody development, from initial target validation to preclinical and clinical development. They also offer a diverse portfolio of proprietary antibody libraries and reagents to meet the specific needs of their clients.

Immunoprecise Antibodies places a strong emphasis on research and innovation, constantly exploring new technologies and approaches to improve their antibody discovery and development processes. This commitment to scientific excellence has established them as a global leader in the field of antibody therapeutics.


   Company Address: 3204 - 4464 Markham Street Victoria 0 BC
   Company Phone Number: 404-1043   Stock Exchange / Ticker: NASDAQ IPA


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CTLT        0.38% 
CYRX   -1.32%    
MNKD        5.04% 
PBYI        1.47% 
TEVA   -2.38%    
VTRS   -0.44%    
• View Complete Report
   



Business Update

ImmunoPrecise Antibodies Ltd. Achieves Nasdaq Compliance and Demonstrates Robust Market Performance

Published Mon, Jul 14 2025 9:17 PM UTC

In recent developments within the biopharmaceutical sector, ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a pioneering company at the confluence of technology, bioinformatics, and biological intelligence, has regained compliance with the Nasdaq Stock Market's minimum bid price requirement. This achievement signifies a critical milestone in the company's growth trajectory and ...

Business Update

Regulatory Innovation ImmunoPrecise Antibodies and FDA Forge a Path to Non-Animal Testing in Drug Developm...

Published Sat, Apr 12 2025 4:43 AM UTC

In the evolving landscape of drug discovery and development, the U.S. Food and Drug Administration (FDA) has recently announced a pivotal shift in its regulatory framework by phasing out animal testing requirements for monoclonal antibodies and other pharmaceutical products. This progressive move marks a significant step in regulatory modernization and underscores the FDA s ...

Business Update

Navigating Innovation ImmunoPrecise Antibodies Aligns with FDAs Non-Animal Testing Initiative Amidst Market Challenges

Published Fri, Apr 11 2025 6:53 PM UTC

In the rapidly evolving landscape of biotherapeutics, ImmunoPrecise Antibodies Ltd. (IPA) is making significant strides in alignment with the U.S. Food and Drug Administration s (FDA) recent push to phase out animal testing methods. The company s proprietary AI-driven platform, LENSai, has placed it at the forefront of this transition, reflecting a growing industry trend tow...

Business Update

ImmunoPrecise Antibodies Stands at the Vanguard of AI-Driven Drug Discovery Revolution,

Published Sat, Mar 29 2025 9:10 AM UTC

ImmunoPrecise Antibodies: Charting a New Frontier in AI-Powered Drug Discovery AUSTIN, Texas In a compelling demonstration of how artificial intelligence can reshape healthcare, ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) has made significant strides in the biotherapeutic research and technology landscape, as outlined in its recent financial results for the third quarter o...

Business Update

Navigating Financial Currents ImmunoPrecise Antibodies Ltd.s Strategic Positioning and AI-Driven Innovations in Q3...

Published Fri, Mar 28 2025 7:56 PM UTC

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), a burgeoning force in the biotechnology sector, has reported its financial results for the third quarter of its fiscal year 2025 (FY25), closing on January 31, 2025. The company s achievements during this critical period not only underscore its commitment to innovation in AI-driven biotherapeutic research but also highlight the in...







Immunoprecise Antibodies Ltd's Segments
United States of America    51.21 % of total Revenue
Europe    44.32 % of total Revenue
Canada    1.59 % of total Revenue
Australia    1.97 % of total Revenue
Other    0.91 % of total Revenue
Project Revenue    90.69 % of total Revenue
Product Sales Revenue    8.3 % of total Revenue
Cryo Storage Revenue    1.01 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com